Combination of monoclonal antibodies or their Fab fragments for the use as the medicament and the pharmaceutical containing these antibodies or their Fab fragments
Abstract
Combination of monoclonal antibodies against growth factors IGF-2 and BMP-4 or their Fab fragments for the use as the medicament, mainly for the use in the treatment of carcinoma, to advantage of head and neck squamous cell carcinoma. Further the solution includes also a pharmaceutical containing monoclonal antibodies against IGF-2 and BMP-4 and eventually also a cytostatic agent.
In advantage monoclonal antibodies are humanized and they can be linked to the soluble polymeric carrier .